Flyer

Brain-derived tau (BD-Tau) is enhancing our understanding of neurodegenerative diseases. As an emerging bloodbased biomarker, BD-Tau is demonstrating potential in distinguishing Alzheimer’s disease (AD) from other neurodegenerative conditions, predicting cognitive decline in AD subgroups, and assessing severe traumatic brain injury (sTBI). The Simoa® BD-Tau Advantage PLUS assay (104797) provides ultra-sensitive and selective measurement of BD-Tau proteins in biological samples. This assay offers new insights to advance research into AD and other neurological conditions. Download our flyer to learn more.